Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Assessment in Adults with Motor, Sensory, and Language Barriers, Following Chimeric Antigen Receptor (CAR) T cell Therapy in the Outpatient Setting | Synapse
March 3, 2026
Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Assessment in Adults with Motor, Sensory, and Language Barriers, Following Chimeric Antigen Receptor (CAR) T cell Therapy in the Outpatient Setting
Key Points
ICANS assessment shows varied symptoms in adults with communication barriers, affecting timely intervention.
Among 30 participants, 67% experienced neurotoxicity symptoms within two months post-CAR T cell therapy.
Observational analysis in outpatient settings explored the impact of barriers on ICANS assessment.
Findings suggest the need for tailored approaches to improve ICANS evaluation in neurodiverse adults.